Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Idea Of The Day -- Ignore unavailable to you. Want to Upgrade?

To: Jerry Olson who wrote (38771)	4/12/2001 7:28:34 AM
From: 2MAR$	Respond to of 50167

OK ..BGEN earns coming in this am , instead of after/hrs here looks like they come in right in line $46 vs $46 Biogen Inc Reports 1Q Results >BGEN Biogen Reports Record Results for First Quarter 2001 Growth Driven by 26 Percent Increase in AVONEX(R) (Interferon beta-1a) Sales; More Than 100,000 Patients Worldwide Now on Therapy CAMBRIDGE, Mass., April 12 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN) today reported financial results for the first quarter of 2001. For the three months ended March 31, 2001, the Company reported a record $220 million in product revenues, representing a 26 percent increase in AVONEX(R) (Interferon beta-1a) sales versus the same period last year. Earnings per share were $0.47 on a reported basis and $0.46 per share before a gain on equity sales, representing a 12 percent increase over last year. (Photo: newscom.com ) James C. Mullen, Biogen's President and Chief Executive Officer, said, "Our strong performance this quarter reflects regained momentum in AVONEX sales. U.S. sales of AVONEX were outstanding, up 28 percent over the same period last year. We have achieved a major milestone, with more than 100,000 patients now on AVONEX therapy. AVONEX continues to be the leading treatment worldwide for MS." Mr. Mullen also said, "In addition to our success in the marketplace, we have made considerable progress at every point in our pipeline, ranging from compounds in research to late-stage clinical trials." During the quarter:

To: Jerry Olson who wrote (38771)	4/12/2001 7:30:05 AM
From: 2MAR$	Read Replies (2) \| Respond to of 50167

second hopeful "buy" recomend for LRCX Lam Research-LRCX reit outperform@SBSH mgt guidance indicates worse is over.... again , hmmmmm... might be good here for a couple will watch , scalped it last night. Micromuse-MUSE initiated coverage with a outperform@SBSH tgt 50 DJN: DJ King Pharma Puts 1Q Net At 24c-25c/Diluted Share >KG JN: DJ Abbott Laboratories 1Q Oper Net 47c/Share Vs Net 44c Applied Micro Circuits-AMCC cut buy to market perform@JPHQ PMC Sierra Inc-PMCS cut long-term buy to market perform@JPHQ